NCT02838940

Brief Summary

Background Preventive antibiotic treatment before performing invasive procedures is a basic element in preventing infections. The essence of preventive antibiotic treatment is strengthening the defense mechanisms of the immune system by preserving a certain drug levels in the blood. The timing of giving the antibiotics is very important. Several research groups have tried to check the levels of Cefazolin (the most common antibiotics in the field of obstetrics) in serum and adipose tissue in women during cesarean. These groups presented conflicting research results. OBJECTIVE This study will discuss the preventive antibiotic treatment levels accepted prior cesareans, to determine:

  1. 1.What are the factors affecting the level of drug in the blood?
  2. 2.Is there a fixed time which beyond it, blood drug levels are below the MIC(Minimal Inhibitory Concentration)?
  3. 3.Is the provision of usual preventive care also addresses the situations of metabolic disorder?

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
250

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Aug 2016

Typical duration for phase_3

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 29, 2016

Completed
2 months until next milestone

First Posted

Study publicly available on registry

July 20, 2016

Completed
12 days until next milestone

Study Start

First participant enrolled

August 1, 2016

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2019

Completed
Last Updated

July 20, 2016

Status Verified

July 1, 2016

Enrollment Period

3 years

First QC Date

May 29, 2016

Last Update Submit

July 17, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Blood antibiotic levels

    Blood MIC(Minimal Inhibitory Concentration) levels of antibiotic will be checked at first incision and at the time of closing surgery.

    30 min- 2 hours.

Study Arms (1)

cesarean in different indications

EXPERIMENTAL

Women that are about to undergo an elective cesarean in different indications.

Procedure: Blood samples.Drug: Cefazolin

Interventions

At the beginning of the first incision in the skin, first blood sample will be taken for levels of antibiotics in serum test. Second blood sample for drug levels in serum test, will be taken while closing the surgical incision in the skin at the end of the operation.

cesarean in different indications

According to the ward protocol prior to the anesthesia by an anesthesiologist, the women will receive one dose of 1 g Cefazolin the usual loading dose. Women with a BMI over 30 will receive Cefazolin of about 2 grams.

cesarean in different indications

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Gestational age of 37 weeks and above.
  • Women who arrive to elective cesareans.
  • Age of women: 18-50 years old.

You may not qualify if:

  • Suspected clinical / laboratory active infection
  • urgent surgery
  • Sensitivity to penicillin or cephalosporins antibiotics that requires antibiotics change.
  • Women who received the week before surgery antibiotic treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Blood Specimen CollectionCefazolin

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative TechniquesCephalosporinsbeta-LactamsLactamsAmidesOrganic ChemicalsThiazinesSulfur CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Yariv Yogev, professor

    Tel Aviv Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Yariv Yogev, professor

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 29, 2016

First Posted

July 20, 2016

Study Start

August 1, 2016

Primary Completion

August 1, 2019

Study Completion

August 1, 2019

Last Updated

July 20, 2016

Record last verified: 2016-07

Data Sharing

IPD Sharing
Will not share